Slide 1: Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI
Ticker: MRIC LD Micro Invitational Investor Presentation June 9, 2016 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “an
Slide 3: MRI Interventions Opportunity
MRI Interventions Opportunity Navigation System Electrode placement for deep brain stimulation for Neurosurgery Laser Ablation for ablation of epileptic foci or Brain Tumors Procedures Brain Tumor Biopsy for deep seated tumors Precise Drug Delivery to target lesions Market potential Market Potential
Slide 4: Leadership: Extensive Med Device Experience
Leadership Extensive Med Device Experience Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank Grillo
Slide 5: Without ClearPoint, minimally invasive neuro
Investor Without ClearPoint, minimally invasive neuro _ _ _ Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real-time visualization Next generation platform enabling real time, MRI guided, minimally invasive brain surgery © 2016 MRI INTERVENTIONS, INC. | 5
Slide 6: ClearPoint Neuro Navigation System
ClearPoint® Neuro Navigation System Integrated Software, Hardware and Single-Use MRI Safe Devices ClearPoint Software Proprietary software for targeting and trajectory calculation / determination Dicom image based SmartFrame®; SmartGrid® ^ _ _ _ _DZ/_ _ _ _DZ/_ _ enable targeting and trajectory calc
Slide 7: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning © 2016 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview Trajectory Alignment & Device Insertion SmartFrame® Hand Controller © 2016 MRI INTERVENTIONS, INC. | 8
Slide 9: ClearPoint Procedure Overview: Delivery of Neurological Therapy
ClearPoint Procedure Overview Delivery of Neurological Therapy Drug Delivery 1 Electrode Placement Laser Ablation 2 (1) Drug Delivery - The SmartFlow® cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during in
Slide 10: Multi-Therapy MRI-Guided Navigational System
Multi-Therapy MRI-Guided Navigational System Notable Neurosurgeon Supporters Dr. Philip Starr Dr. Paul Larson Dr. Robert Gross Dr. Robert Wharen, Jr. ASSFN Past President UCSF & VA Emory University Mayo Clinic -Jacksonville Published Peer-Reviewed Journal Support Compatible With Multiple Therapies V
Slide 11: Patented Intellectual Property
Patented Intellectual Property Over 100 issued patents around the world 20+ U.S. 30+ OUS 70+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame® trajectory guide; other
Slide 12: Patient Impact
Patient Impact D _^ C l e a r Po i nt - E n a b l e d E l e c t ro d e P l a c e m e nt © 2016 MRI INTERVENTIONS, INC. | 12
Slide 13: Patient Benefit
Patient Benefit Minimally Invasive Procedure 7 days after ClearPoint procedure Arrow Indicates Surgery Site INC. | 13
Slide 14: Drug Delivery: Seven Programs Underway
_ W _h _ __ _Delivery Seven Programs Underway Now... Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery of almost all drugs 98% of small molecules - Direct injection without ClearPoint is blind, so target is frequently missed - Neopharm Trial - 51% of 57
Slide 15: ClearPoint Drug Delivery
ClearPoint Drug Delivery MR visualization of neuro target Growing Set of Peer-UHYLHZHG_3XEOLFDWLRQV≪ MR-guided placement of catheter Therapeutic agent delivered under MR-guidance* Specialized, FDA-FOHDUHG_GUXJ_GHOLYHU\_FDQQXOD V___ catheters Conclusion: The ClearPoint system allows Real-time Convect
Slide 16: The ClearPoint Difference
Uses other than the approved indication are limited by Federal law to investigational use. The ClearPoint Difference With ClearPoint Without ClearPoint (Stereotactic) Direct, high resolution visualization; Performed in No direct visualization; Performed in an operating room an MRI Suite Highly accur
Slide 17: ClearPoint Revenue Model
ClearPoint Revenue Model B U S I N ES S M O D E L R A ZO R / R A ZO R B L A D E ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existi
Slide 18: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 45 sites in the US Emory University Hospital UCSF Medical Center Europe: Warsaw, Poland _ _ _t _ Hospital © 2016 MRI INTERVENTIONS, INC. | 18
Slide 19: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity W Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis) Prevalence Drug Treatment 125,000 264,000 Resistant (DTR) 7,500 18,000 Resections: 80,000 Incidence DTR Stereotactic Biopsy: 10,000 Electrode Laser Ablation Biopsy / Laser Abl
Slide 20: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues Consumables $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 2016 © 2016 MRI INTERVENTIONS, INC. | 20
Slide 21: Total Revenue
Total Revenue, 2013 - 2015 $1,600,000 Total Revenue $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 2016 Consumables Capital / Service Other © 2016 MRI INTERVENTIONS, INC. | 21
Slide 22: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2014 2015 2016 © 2016 MRI INTERVENTIONS, INC. | 22
Slide 23: Commercial Priorities Driving Adoption of the ClearPoint System
Commercial Priorities Driving Adoption of the ClearPoint System Focus on adding surgeons at existing accounts Increase Target high volume sites, including epilepsy and tumor neurosurgeons within each Utilization account; gain greater share of their procedures Add Clinical Specialists and sales reps
Slide 24: At the Center of an Emerging Industry Trend
At the Center of an Emerging Industry Trend ClearPoint ClearPoint MRIC is at the point of Electrode Laser Catheter Placement Placement convergence in an industry trend impacting Real Time MRI- some of the most ClearPoint Guided ClearPoint Direct Drug Procedures Performed influential and Delivery in
Slide 25: MRI Interventions, Inc. contact
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 25